Eli Lilly upgraded its relationship with Insilico Medicine, converting a prior software licensing arrangement into a joint drug-discovery partnership. The companies disclosed the collaboration could be worth more than $100 million, including upfront payments, milestones and tiered royalties tied to programs discovered via Insilico’s Pharma.AI platform. Lilly will pair its therapeutic development expertise with Insilico’s AI models to advance discovery on Lilly-defined targets. The deal follows an earlier 2023 licensing pact and coincides with Lilly’s wider investment in in-house AI infrastructure, including deployment of an NVIDIA DGX SuperPOD for internal discovery operations.